Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823887 | 0.90 | MCHR1 (0.38) | MCHR1MAPTPOLBMAPK1ACACB | |
| SCHEMBL1828390 | 0.87 | ALDH1A1 (0.41) | MAPTPOLBMAPK1ACACBALDH1A1 | |
| SCHEMBL2252368 | 0.85 | MEN1 (0.37) | MCHR1MAPTMAPK1ACACBALDH1A1 | |
| SCHEMBL2244382 | 0.84 | ADAMTS5 (0.41) | MAPTMAPK1ACACBALDH1A1ADORA3 | |
| SCHEMBL2241918 | 0.84 | LIPE (0.40) | MCHR1MAPTACACB | |
| SCHEMBL2247202 | 0.83 | ALDH1A1 (0.43) | MAPTPOLBMAPK1ACACBALDH1A1 | |
| SCHEMBL2253918 | 0.83 | MAPT (0.46) | MAPTMAPK1ALDH1A1TP53ADORA3 | |
| SCHEMBL2244670 | 0.82 | ADORA3 (0.43) | MAPTCYP2D6ALDH1A1ADORA3HTR2A | |
| SCHEMBL2247318 | 0.82 | MAPT (0.47) | MAPTALDH1A1TP53 | |
| SCHEMBL2247475 | 0.82 | LMNA (0.42) | MAPTMAPK1ACACBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660471-B1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1660471-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019194-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LIMITED (GB) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | MMP13, MMP3, MMP1 | MCHR1 3548/4885MAPT 4843/4885POLB 2657/4885 |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | MMP3, MMP1, MMP13 | MCHR1 3908/4885MAPT 4094/4885POLB 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.